N201 / TCRCure - LARVOL DELTA

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: TCRCure Biopharma Ltd. | Trial completion date: Mar 2025 ➔ Dec 2026 | Trial primary completion date: Oct 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Solid Tumor • CTAG1B

Activation of astrocytic NMDA receptors counteracted Aβ-induced reduction of BDNF and elevation of GFAP and complement 3 in the hippocampal astrocytes. (PubMed, Neuroscience) - "Our results showed that activation of astrocytic NMDARs by 1 μM NMDA rescued Aβ-induced reduction of brain-derived neurotrophic factor (BDNF), and inhibited Aβ-induced increase of GFAP, complement 3 (C3) and activation of NF-κB Furthermore, blockade of astrocytic GluN2A with TCN201 abrogated the ability of 1 μM NMDA to counteract the effects of Aβ decreasing BDNF, and increasing GFAP, C3 and activation of NF-κB. These findings suggest that activation of astrocytic NMDARs protect against Aβ-induced synaptotoxicity probably through elevating BDNF and suppressing GFAP and C3. Our present research provides valuable insights for elucidating the underlying mechanism of astrocytic NMDARs activation resisting the toxic effects of Aβ."

Journal • BDNF • GFAP • GRIN2A

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: TCRCure Biopharma Ltd. | Phase classification: P1/2 ➔ P1 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Metastases • Phase classification • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor • CTAG1B

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: TCRCure Biopharma Ltd.

Metastases • New P1/2 trial • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor • CTAG1B